These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1286541)

  • 1. Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy.
    Boyd K; Rogers C; Boreham C; Andrews WJ; Hadden DR
    Diabetes Res; 1992 Feb; 19(2):69-76. PubMed ID: 1286541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.
    Marena S; Tagliaferro V; Montegrosso G; Pagano A; Scaglione L; Pagano G
    Diabete Metab; 1994; 20(1):15-9. PubMed ID: 8056129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
    BMJ; 1995 Jan; 310(6972):83-8. PubMed ID: 7833731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glyburide in non-insulin-dependent diabetes. Its therapeutic effect in patients with disease poorly controlled by insulin alone.
    Lardinois CK; Liu GC; Reaven GM
    Arch Intern Med; 1985 Jun; 145(6):1028-32. PubMed ID: 3923961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
    Erle G; Lovise S; Stocchiero C; Lora L; Coppini A; Marchetti P; Merante D
    Acta Diabetol; 1999 Jun; 36(1-2):61-5. PubMed ID: 10436254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    DeFronzo RA; Goodman AM
    N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
    Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
    Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus.
    Groop L; Widén E; Franssila-Kallunki A; Ekstrand A; Saloranta C; Schalin C; Eriksson J
    Diabetologia; 1989 Aug; 32(8):599-605. PubMed ID: 2506091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes.
    Garber A; Marre M; Blonde L; Allavoine T; Howlett H; Lehert P; Cornes M
    Diabetes Obes Metab; 2003 May; 5(3):171-9. PubMed ID: 12681024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
    Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
    Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study.
    Gulias-Herrero A; Aguilar-Salinas CA; Gómez-Pérez FJ; Rull JA
    Diabetes Nutr Metab; 2003; 16(5-6):268-76. PubMed ID: 15000437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of fasting hyperglycaemia with insulin or sulphonylurea lowers fasting ketone levels, but does not alter resting or post-glucose energy expenditure in non insulin dependent diabetes. Differences between the OGTT and the glucose clamp.
    Boyd K; Boreham C; Andrews WJ; Hadden DR
    Diabetes Res; 1991 Nov; 18(3):101-8. PubMed ID: 1841819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity.
    Kabadi UM; McCoy S; Birkenholz M; Kabadi M
    Diabet Med; 1995 Oct; 12(10):880-4. PubMed ID: 8846678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.